Announcements 2025

(Unaudited Financial Data) Significant Sales and EBITDA Growth – Strong increase in net profit   Paiania, 19 March 2025 - Lavipharm S.A. informs the investment community on the key financial figures for the fiscal year 2024, as well as the Group’s operational developments to date: Consolidated Sales from ongoing...

Paiania, 14 March 2025 – Lavipharm S.A., pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces its Financial Calendar for 2025, as follows:   Wednesday, 19 March 2025 Flash Note on Financial Results of FY 2024 Thursday, 3 April 2025 Announcement of FY 2024 Financial Report Thursday, 24...

Paiania, 4 February 2025 – Lavipharm S.A., a Pharmaceutical, Chemical, and Cosmetic Products Commercial and Industrial Societe Anonyme (hereinafter the “Company”), announces, in accordance with the provisions of Article 19 of Regulation (EU) No. 596/2014 and following a relevant notification received, that on 3 February...

Peania, 23 January 2025 – Lavipharm announces a strategic commercial agreement with the multinational company iNova Pharmaceuticals, the owner of Betadine® and other trusted brands. The new partnership involves the licensing rights of a new antiseptic pharmaceutical OTC product developed by Lavipharm to be commercialized by...